Status:
UNKNOWN
Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma
Lead Sponsor:
Ruijin Hospital
Conditions:
Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics
Eligibility:
All Genders
18+ years
Brief Summary
A large-scale, high-throughput, multi-dimensional comprehensive study of PDAC multiomics will be carried out. In this study, clinical specimens of resected PDAC collected by our research group from 20...
Eligibility Criteria
Inclusion
- The diagnosis of pancreatic cancer was confirmed by histological examination or fine needle aspiration cytology;
- The tumor was graded according to THE WHO standard, and the tumor stage was graded according to the TNM stage;
Exclusion
- The inclusion criteria of the above groups were not met;
- There are few tissue specimens, only enough for clinical diagnosis;
- Patients are unwilling to conduct follow-up study;
- For the new diagnosed patient, radiotherapy or chemotherapy have been given in the previous three months;
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04525209
Start Date
October 1 2020
End Date
December 31 2022
Last Update
August 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
RUIJIN Hospital
Shanghai, Shanghai Municipality, China, 200025